Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.
about
Hepatic hemodynamic changes during liver transplantation: a reviewPrevention of portal hypertension: from variceal development to clinical decompensationCardiovascular dysfunction in patients with liver cirrhosisEndothelial dysfunction in cirrhosis: Role of inflammation and oxidative stressOxidative Stress and Liver Cancer: Etiology and Therapeutic TargetsAngiogenesis and liver fibrosis11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertensionIncreased EETs participate in peripheral endothelial dysfunction of cirrhosisNormalization of the vasculature for treatment of cancer and other diseases.Hepatic and Plasma Endothelin-1 in Dogs with Chronic HepatitisA transgenic model for conditional induction and rescue of portal hypertension reveals a role of VEGF-mediated regulation of sinusoidal fenestrations.Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats.Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesisUpregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis.A pharmacodynamic model of portal hypertension in isolated perfused rat liverNADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft RecruitmentYiguanjian decoction and its ingredients inhibit angiogenesis in carbon tetrachloride-induced cirrhosis mice.Heterogeneity in apoptotic responses of microvascular endothelial cells to oxidative stress.Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosisCelecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.Relationship between tetrahydrobiopterin and portal hypertension in patients with chronic liver disease.Coagulation in hepatobiliary disease.Recent advances in our understanding of hepatorenal syndrome.Potential for statins in the chemoprevention and management of hepatocellular carcinoma.Current concepts on the role of nitric oxide in portal hypertension.Future treatments of cirrhosis.Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspectsNew cellular and molecular targets for the treatment of portal hypertension.Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement.Complications of cirrhosis. A 50 years flashback.Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis.Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.Murine junctional adhesion molecules JAM-B and JAM-C mediate endothelial and stellate cell interactions during hepatic fibrosis.Advances in the treatment of portal hypertension in cirrhosis.Emerging therapies for portal hypertension in cirrhosis.Angiogenesis and Fibrogenesis in Chronic Liver Diseases.Portal hypertension: Imaging of portosystemic collateral pathways and associated image-guided therapy.Protein kinase G signaling disrupts Rac1-dependent focal adhesion assembly in liver specific pericytesA randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.Thrombophilic Genetic Factors PAI-1, MTHFRC677T, V Leiden 506Q, and Prothrombin 20210A in Noncirrhotic Portal Vein Thrombosis and Budd-Chiari Syndrome in a Caucasian Population.
P2860
Q26822255-E1D42BC8-6F13-4989-A713-05B10A64502EQ26865665-340261C9-974A-4BDA-8DE3-1A3E0107421CQ27010592-CE2E831F-0B53-4903-B21F-DE8BA5811C0DQ27023122-D453C0FF-4911-429F-84C9-935FEAEED5D7Q28071678-BC12595B-C98C-408E-B077-584B55005807Q28082569-BF9C60BE-58EE-4251-B65E-7C6F2E0C41DBQ28246053-236BCD14-1A1B-47AF-9AA3-E2467C49F2ACQ28257472-57B297EE-900B-46F4-B912-9F5DF273EAEEQ30471456-68125999-17A5-4A70-94E3-F238EAE0C342Q33698521-8CF92FB4-1AFF-4314-9976-10BD83DB372CQ33968080-059EDFC6-4B9C-485A-808F-D28E4D2F229DQ34589780-3246CFBC-C81C-486C-95F7-9EF7471323C9Q34902424-3FCB2232-7BF1-4CE8-9A5C-47E0811F8293Q35057717-89F82F27-44BA-49D9-B621-727AAE1D4F61Q35725863-B66CFC4F-3FD3-4488-A4E8-3C0A640B32AFQ35790133-882755AF-83EB-4396-892B-EBDE8641E0AAQ35795593-A8EA5EFC-7216-4C1D-8987-28F262D106FCQ36496994-D85C018E-F5BA-47E0-BD29-728239895223Q36875004-E701596D-33BA-490C-93B0-1D6DC2F343A6Q37262768-95829540-BC7A-4D26-BA18-08C5C98E2C13Q37622223-D077AB38-1CAD-4F75-B5AE-0E2CA66B1939Q37982415-AADB8FE2-910D-4693-AFD1-464EBF509703Q38012022-99F1F68B-A6E9-4F1B-BCD3-7A4853CF6B00Q38030991-9153AC5E-C040-4391-B72E-22E0C586CED5Q38095931-6DAC4BC0-EE0B-407B-9AD9-9468EB5060A5Q38218607-5B95FFF9-D4B7-4D5C-B0F2-5DF7724E4943Q38268612-8B3D50FB-509B-449C-8CD3-858F699BD75AQ38383418-59BD58EC-DBB6-4154-A828-7B9010678394Q38417924-08587346-1151-46DA-94D8-28F53F490996Q38424360-34DE0DDB-F1C8-4088-97E6-7C25D4959C18Q38618343-0E9CC99F-009B-4A91-BAEE-86C3D8368C71Q38635623-7E2C702B-39F2-4645-BCE7-141277C92D8FQ38775599-3DE117CF-80D5-4777-89A0-DBE42F9FF8FEQ38776991-FA0D39B8-2824-442B-B1DF-0B5ACEE10D8BQ38826464-FCAEF01A-5840-4804-9B1A-4161DD205C8BQ39140170-A7566A6E-EA31-4588-99EC-36B74BE73BFEQ39203632-370DBE8F-FB9F-48A1-9E93-34E062632943Q39568078-D2E456ED-1936-4F05-A147-883BBF5776BDQ40375007-B5BB4928-B39E-4A67-A298-60A59CC63F5CQ41850472-0D054EC5-4875-4A62-BBDB-E284E9202698
P2860
Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatic endothelial dysfunctio ...... atment of portal hypertension.
@en
Hepatic endothelial dysfunctio ...... atment of portal hypertension.
@nl
type
label
Hepatic endothelial dysfunctio ...... atment of portal hypertension.
@en
Hepatic endothelial dysfunctio ...... atment of portal hypertension.
@nl
prefLabel
Hepatic endothelial dysfunctio ...... atment of portal hypertension.
@en
Hepatic endothelial dysfunctio ...... atment of portal hypertension.
@nl
P1476
Hepatic endothelial dysfunctio ...... eatment of portal hypertension
@en
P2093
Jaume Bosch
Juan G Abraldes
P304
P356
10.1016/J.JHEP.2010.03.021
P577
2010-06-01T00:00:00Z